Johnson Investment Counsel Inc. Raises Position in Stryker Corporation $SYK

Johnson Investment Counsel Inc. grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,486 shares of the medical technology company’s stock after purchasing an additional 9,227 shares during the period. Johnson Investment Counsel Inc. owned approximately 0.05% of Stryker worth $80,901,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sachetta LLC lifted its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Stryker in the 1st quarter valued at $32,000. Ridgewood Investments LLC increased its position in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares during the period. Ransom Advisory Ltd acquired a new position in shares of Stryker in the 1st quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker in the 1st quarter valued at $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $364.77 on Friday. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $139.46 billion, a P/E ratio of 48.31, a P/E/G ratio of 2.63 and a beta of 0.94. The business’s 50-day moving average is $380.25 and its two-hundred day moving average is $378.83.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the firm earned $2.81 EPS. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research reports. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research report on Wednesday. Wells Fargo & Company upped their target price on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Rothschild Redb raised Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.